Absolutely agree , look at the rewards to Acadia for bringing 2 rare disease neurological drugs to market ? Today they are worth less than they were BEFORE Nuplazid passed phase 3 and got approved and BEFORE they took Trofinetide through the same costly process . They are valued at what they were in 2015 !!!
What's the point going ahead with these outcomes ?
Acadia, page-794
-
- There are more pages in this discussion • 52 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.82 |
Change
0.205(1.51%) |
Mkt cap ! $1.784B | |||
| Open | High | Low | Value | Volume |
| $13.60 | $14.00 | $13.51 | $2.897M | 209.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 147 | $13.81 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.82 | 716 | 18 |
View Market Depth
| Last trade - 15.38pm 13/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |